Diabetes Technology Society, Burlingame, CA, USA.
Stanford University, Stanford, CA, USA.
J Diabetes Sci Technol. 2022 May;16(3):775-782. doi: 10.1177/19322968221078884. Epub 2022 Feb 28.
Continuous subcutaneous insulin infusion (CSII) therapy is becoming increasingly popular. CSII provides convenient insulin delivery, precise dosing, easy adjustments for physical activity, stress, or illness, and integration with continuous glucose monitors in hybrid or other closed-loop systems. However, even as insulin pump hardware and software have advanced, technology for insulin infusion sets (IISs) has stayed relatively stagnant over time and is often referred to as the "Achilles heel" of CSII. To discuss barriers to insulin pump therapy and present information about advancements in, and results from clinical trials of extended wear IISs, Diabetes Technology Society virtually hosted the "Improving the Patient Experience with Longer Wear Infusion Sets Symposium" on December 1, 2021. The symposium featured experts in the field of IISs, including representatives from Steno Diabetes Center Copenhagen, University of California San Francisco, Stanford University, Medtronic Diabetes, and Science Consulting in Diabetes. The webinar's seven speakers covered (1) advancements in insulin pump therapy, (2) efficacy of longer wear infusion sets, and (3) innovations to reduce plastics and insulin waste.
持续皮下胰岛素输注(CSII)治疗越来越受欢迎。CSII 提供了方便的胰岛素输送、精确的剂量、便于根据体力活动、压力或疾病进行调整,并且可以与混合或其他闭环系统中的连续血糖监测器集成。然而,即使胰岛素输注系统(IIS)的硬件和软件已经得到了改进,IIS 的技术随着时间的推移相对停滞不前,通常被称为 CSII 的“阿喀琉斯之踵”。为了讨论胰岛素泵治疗的障碍,并介绍延长使用 IIS 的进展和临床试验结果,糖尿病技术协会于 2021 年 12 月 1 日虚拟举办了“改善患者使用延长佩戴输注系统的体验研讨会”。该研讨会的特色是 IIS 领域的专家,包括来自哥本哈根 Steno 糖尿病中心、加州大学旧金山分校、斯坦福大学、美敦力糖尿病和糖尿病科学咨询的代表。网络研讨会的七位演讲者涵盖了(1)胰岛素泵治疗的进展,(2)延长佩戴输注系统的疗效,以及(3)减少塑料和胰岛素浪费的创新。